Highlights:
- Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company's safety and quality standards.
- Optimi experts will address critical inquiries which still exist on the definition of validated GMP psilocybin, MDMA, and other psychedelic substances.
- Optimi is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs.
VANCOUVER, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi"), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is announcing an informative webinar titled "Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy." This event, scheduled for Tuesday, February 13, 2024, at 2:00 p.m. Pacific Standard Time (PST), is a crucial opportunity for clinicians, scientists, researchers, therapists, pharmacists, and regulators involved or interested in the GMP manufacturing of psychedelic drug substances.
The session will be hosted by Optimi Health Chief Science Officer, Dr. Preston A. Chase, and Director of Quality Commercial Strategies, Karina Lahnakoski. Both individuals, considered experts in their respective fields, currently lead the Company's cutting-edge science and quality assurance divisions. The webinar aims to provide invaluable educational insights into the meticulous processes involved in ensuring the quality, safety, and international supply of the Company's psychedelic drug candidates.
"Professionals aiming for a thorough grasp of the importance and impact of maintaining rigorous standards in psychedelic drug manufacturing and formulation are urged to attend," stated Chase and Lahnakoski. "Our responsibility, extending from the laboratory to the patient, is to consistently achieve and uphold the utmost quality benchmark, gauged by accountability and trust. It is paramount for Optimi to showcase its leadership in the industry by highlighting unparalleled product quality and excellence, setting a standard for the world to witness."
On December ...